Acotec Scientific Holdings Limited board of directors announced that on March 20, 2024, the Group received the registration approvals from the PRC National Medical Products Administration for YIYAN Coronary High-Pressure Dilatation Balloon, a product designed for dilating in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. The Company will carry out marketing activities in PRC market when appropriate.
Acotec Scientific Holdings Limited
Equities
6669
KYG0096M1096
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.67 HKD | -3.33% | +1.37% | -40.87% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-40.87% | 276M | |
+73.43% | 12.41B | |
-16.51% | 8.14B | |
+16.03% | 7.2B | |
+4.95% | 5.93B | |
+13.07% | 5.43B | |
+36.46% | 4.89B | |
-19.24% | 4.09B | |
-34.06% | 2.49B | |
+1.73% | 2.04B |
- Stock Market
- Equities
- 6669 Stock
- News Acotec Scientific Holdings Limited
- Acotec Scientific Holdings Limited Receives Approval for Yiyan Coronary High-Pressure Dilatation Balloon by Prc National Medical Products Administration